Lyxumia by Sanofi stops supply in the second half

Due to the company's circumstances, withdrawal of item permission next month

Inventory to be exhausted by June this year

Sanofi-Aventis Korea

Sanofi-Aventis Korea's supply of GLP-1 analog diabetes treatment ‘Lyxumia (Lixisenatide)’ will be discontinued from June this year.

 

According to the distribution industry on the 7th, Sanofi recently announced that it has stopped supplying two formulations, such as 10μg and 20μg of Lyxumia pen, due to company circumstances.

 

Sanofi said in an announcement that it is scheduled to withdraw its product license (from the Ministry of Food and Drug Safety) for the convenience of the company.

 

If Lyxumia is withdrawn in March, the supply is expected to cease in June this year, when inventory held by wholesalers is exhausted.

 

The remaining benefit period is expected to be up to six months from the date of withdrawal.

 

As a result, benefits are expected to cease from October this year.

 

The reason for the withdrawal of Lyxumia is unknown.

 

However, the rapid decline in revenue after the advent of competitive products is believed to have had some effect on supply disruption.

 

Licensed as a GLP-1 analogue in March 2013 by the Food and Drug Administration, the product was approved for glycemic control, diet and exercise therapy supplements in adult patients with type 2 diabetes.

 

At the time of the market, once-daily administration showed attention for lowering blood sugar regardless of pre and post meal.

 

However, Lixumia's sales declined sharply in 2016 because of Trulicity (Dulaglutide), which is administered once a week with the same GLP-1 analog family.

 

According to drug market research institutes such as IQVIA, The sales fell to ₩500 million in 2018 and ₩300 million in 2019.

 

The poor performance of the family of GLP-1 analogs administered once a day is not the only Lixumia.

 

Victoza (Liraglutide) by Novonordisk and Byetta(Exenatide) by Astrazeneca also fell below ₩100 million.

 

At present, the market size of the GLP-1 analogue is known to be about ₩30 billion.

 

The industry believes that it is due to the convenience of once-weekly administration and Trulicity, which is recognized for its combination with basal insulin at the end of 2017.

 

The long-lasting product has reduced the rejection of injections.

 

This is a long-lasting product that has increased convenience.

 

The market grew, but as Trulicity encroached, once-daily dosing products gradually disappeared.